j. med. chem. 2004, 47, 2475-2485

2475

synthesis of 2,4-diamino-6-[2â€²-o-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of pneumocystis carinii,
toxoplasma gondii, and mycobacterium avium  xxxg631xxx 
andre rosowsky,*,â€  hongning fu,â€  david c. m. chan,â€  and sherry f. queenerâ€¡
dana-farber cancer institute and department of biological chemistry and molecular pharmacology, harvard medical school,
boston, massachusetts 02115, and department of pharmacology and toxicology, indiana university school of medicine,
indianapolis, indiana 46202
received november 26, 2003

six previously undescribed n-(2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepines with watersolubilizing o-carboxyalkyloxy or o-carboxybenzyloxy side chains at the 2â€²-position were
synthesized and compared with trimethoprim (tmp) and  xxxd2968xxx  (ptx) as inhibitors of
 xxxg631xxx  (dhfr) from pneumocystis carinii (pc), toxoplasma gondii (tg), and
mycobacterium avium (ma), three of the opportunistic organisms known to cause significant
morbidity and mortality in patients with aids and other disorders of the immune system.
the ability of the new analogues to inhibit reduction of dihydrofolate to tetrahydrofolate by
pc, tg, ma, and rat dhfr was determined, and the selectivity index (si) was calculated from
the ratio ic50(rat dhfr)/ic50(pc, tg, or ma dhfr). the ic50 values of the 2â€²-o-carboxypropyl
analogue (10), with si values in parentheses, were 1.1 nm (1300) against pc dhfr, 9.9 nm
(120) against tg dhfr, and 2.0 nm (600) against ma dhfr. the corresponding values for
the 2â€²-o-(4-carboxybenzyloxy) analogue (12) were 1.0 nm (560), 22 nm (21), and 0.75 nm (630).
by comparison, the ic50 and si values for tmp were pc, 13 000 nm (14); tg, 2800 nm (65);
and ma, 300 nm (610). for the prototypical potent but nonselective inhibitors ptx and tmx,
respectively, these values were pc, 13 nm (0.26) and 47 nm (0.17); tg, 4.3 nm (0.76) and 16
nm (0.50); ma, 0.61 nm (5.4) and 1.5 nm (5.3). thus 10 and 12 met the criterion for dhfr
inhibitors that combine the high selectivity of tmp with the high potency of ptx and tmx.
introduction
despite the considerable number of active new antiretroviral agents and a growing understanding of the
origin and potential means of circumvention of drug
resistance to these agents, typically through the use of
multidrug cocktails,1,2 major progress in the treatment
of aids has thus far been confined to the economically
most affluent countries of the world. as a result of
limited access to these often very costly antiviral
medications in underdeveloped nations,3 disabling and
often life-threatening opportunistic infections by various
parasites to which aids patients are especially vulnerable4 are a global public health concern with major
social and political implications.5 among the more
prevalent of these infections, and indeed in some cases
the earliest event signaling t-cell destruction by the
hiv-1 or hiv-2 virus, are those caused by the opportunistic organisms pneumocystis carinii (pc),6 toxoplasma gondii (tg),7,8 mycobacterium avium (ma),9 and
cryptosporidium parvum (cp),10 to name just four.
because of the severe impact that infections by these
often coexisting parasites can have on the duration and
quality of life of aids patients, and because a general
concensus is lacking as to the proper length of treatment
with antiparasitic drugs once intensive multidrug antihiv therapy has brought down the number of virus
* to whom correspondence should be addressed. phone: 617-6323117. fax: 617-632-2410. e-mail: andre_rososwky@dfci.harvard.edu.
â€  dana-farber cancer institute.
â€¡ indiana university.

particles in the blood to very low levels, efforts are
continuing to find newer agents that can complement
the currently available drugs for treatment and/or
prophylaxis of hiv-associated opportunistic infections.
our laboratory11 and others12-15 have been engaged
since the early 1990s in the design and synthesis of
small-molecule inhibitors of  xxxg631xxx 
(dhfr), in the hope of finding agents that would be
superior to two-drug antifolate regimens combining, for
example, an inhibitor of dihydropteroate synthetase
(e.g., sulfamethoxazole or dapsone) with a dhfr inhibitor such as trimethoprim (1) or pyrimethamine (2).16
coadministration of the sulfa drug is typically required
in the case of trimethoprim because the latter, when
given alone, is not potent enough to completely eradicate
the infection. however many patients develop severe
allergic skin reactions to sulfa drugs17 and therefore
have to discontinue treatment before a complete cure
is achieved. furthermore, given the fact that only
mutations in dihydropteroate synthetase, and not dhfr,
have been observed in resistant pc strains, investigators
are beginning to question the role of trimethoprim in
 xxxd1734xxx  (trimethoprim + sulfamethoxazole), the
two-drug combination almost universally prescribed for
pc prophylaxis.18 a much more potent dhfr inhibitor
than trimethoprim, approved a few years ago for use in
aids patients suffering from pneumocystis carinii
pneumonia, is  xxxd3442xxx  (3).19 unlike trimethoprim,
which is much more selective in its ability to bind
selectively to pc dhfr and other opportunistic para-

10.1021/jm030599o ccc: $27.50 Â© 2004 american chemical society
published on web 04/10/2004

2476

journal of medicinal chemistry, 2004, vol. 47, no. 10

rosowsky et al.

sites as compared with human dhfr,  xxxd3442xxx 
lacks this selectivity and therefore requires coadministration of  xxxd2462xxx  ( xxxd2462xxx ) to
selectively protect the patient from severe hematologic
side effects that would otherwise occur.  xxxd2968xxx  (4)

dhfr than trimethoprim. in a subsequent study, the
3d structure of the ternary complex of 6 and nadph
with pc dhfr was analyzed by crystallography, and
an unusual role was uncovered for the dibenz[b,f]azepine moiety in positioning the diaminopteridine
within the active site.23
in an assay based on measurement of [3h]uracil
incorporation into the dna of tg tachyzoites in culture,
6 had an ic50 of 0.077 Âµm22 and thus was roughly 100
times more potent than pyrimethamine. reasonable
growth inhibition was also observed against intact p.
carinii organisms grown on monolayers of human
embryonic lung fibroblasts (with  xxxd2146xxx  present in
the medium in order to protect the feeder cells). the
ic50 of 6 in this assay was estimated to be ca. 2 Âµm,
whereas trimethoprim had essentially no effect.22 although the methods used to compare activity against
intact pc and tg organisms were different, there was
reasonable consistency between the dhfr inhibition
data on one hand and the growth inhibition data on the
other. in sum, 6 appeared to be a promising starting
point from which to launch structure-activity optimization with both species, as well as ma, as targets.
the results with other compounds in our original
study22 suggested that the dibenz[b,f]moiety might be
contributing in a major way to the structure-activity
and structure-selectivity profile. an attempt to enhance
the potency of 6 by replacing the pteridine ring with a
 xxxd3047xxx [2,3-d]pyrimidine or quinazoline, or by interchanging the azepine ring nitrogen and ch2 bridge, did
not yield encouraging results.24 however, we now report
that a substantial improvement in potency and selectivity against not only tg dhfr but also pc and ma dhfr
can be realized by modifying the 2â€²-position of the
dibenz[b,f]azepine ring as in structures 7-12. the
carboxylic acid side chain in these compounds is also
present as a key structural motif in several recently
studied 2,4-diamino-5-(2â€²,5â€²-disubstituted benzyl)]pyrimidines from this laboratory.11a,b the best of the new
analogues reported here is 2,4-diamino-6-[2â€²-o-(3-carboxypropyl)oxydibenz-[b,f]azepin-5-yl]methylpteridine
(10), which has an ic50 of 1.1 nm against pc dhfr and
a remarkable selectivity index of 1300 (95% confidence
interval ) 850-2000) for pc versus rat dhfr. compound 10 is also very potent and selective against ma
dhfr, but is less selective against the tg enzyme than
against the pc or ma enzyme. to our knowledge, it is
among the most potent and selective inhibitors of pc
dhfr reported to date.

closely resembles  xxxd3442xxx  in that it has very high
affinity for dhfr, but lacks selectivity and thus requires  xxxd2462xxx  coadministration.20 the explanation
generally given for this selectivity of protection is that
the parasites synthesize their own reduced folate cofactors de novo and therefore, in contrast to mammalian
cells, have no need for folate transporter proteins in
their cell membrane.21 given the limitations of both the
trimethoprim/sulfa and  xxxd3442xxx / xxxd2462xxx  regimens mentioned above, a single dhfr inhibitor combining the potency of  xxxd3442xxx  (or  xxxd2968xxx ) with
the species selectivity of trimethoprim would be desirable, in that it would eliminate the need to coadminister
either a sulfa drug or  xxxd2462xxx .
in 1999 we reported the synthesis of a novel group of
2,4-diaminopteridine dhfr inhibitors containing a
lipophilic tricyclic group at the 6-position, as exemplified
by general structure 5.22 the most interesting member
of the series was the dibenz[b,f]azepine 6, whose potency

chemistry

and selectivity against pc dhfr were only moderate,
but whose potency against tg dhfr approached that
of  xxxd3442xxx . moreover, while  xxxd3442xxx  was a
better inhibitor of the mammalian dhfr (in this case
the rat enzyme) and thus was completely devoid of
selectivity, 6 showed a 100-fold binding preference for
tg dhfr. compound 6 was also several times more
potent and selective against ma dhfr than rat dhfr
and was a much better inhibitor of both tg and ma

the synthesis of compounds 7-12 from dibenz[b,f]azepine (iminostilbene, 13) is depicted in scheme 1 and
required us to prepare the key intermediate 5h-dibenz[b,f]azepin-2-ol (15) which was obtained essentially as
described in the literature.25,26 oxidation of 13 with
potassium nitrosodisulfonate (fremyâ€™s salt) at 5 Â°c
overnight in a mixture of acetone and potassium phosphate buffer adjusted to precisely ph 7.22 afforded the
deep-red iminoquinone 14 in 77% yield. also formed,
and easily separated by silica gel chromatography, was
a small amount (ca. 10%) of acridine-9-carboxaldehyde,
readily identified by the presence in its 1h nmr
spectrum of a singlet at delta 11.5 for the aldehyde proton.

 xxxg631xxx  inhibitors

journal of medicinal chemistry, 2004, vol. 47, no. 10 2477

scheme 1a

a reagents: (a) fremyâ€™s salt, na hpo , aq me co; (b) na s o , chcl ; (c) tbdmscl, et n, chcl ; (d) 16, na co , mecn; (e)
2
4
2
2 2 4
3
3
3
2
3
h2nc(dnh)nh2, naoet, etoh; (f) brch2(x)co2et, naoet, dmso, or brch2co2h, dmso; (g) naoh.

some unchanged 13 (ca. 10%) was also recovered and
could be recycled. the 1h nmr spectrum of purified 14
featured a well-defined pair of doublets at delta 7.20 and delta
7.57 which we assigned to the 10,11-double bond. the
lower-field doublet at delta 7.57 was tentatively assigned
to the proton at the 11-position on the basis of its closer
proximity to the electronegative oxygen on the quinone
ring. it should be noted that a number of reaction
conditions based on literature examples of the use of
fremyâ€™s salt27 were investigated with the aim of minimizing the formation of side products in this somewhat
capricious oxidation. the ph should optimally be maintained between 7.2 and 8.3, as the yield drops when the
ph is <7.2, whereas a large amount of tar forms when
the ph is >8.5. it is also important to continuously
purge the system with argon during rotary evaporation
of the reaction mixture to dryness. and finally, because
14 is somewhat unstable when adsorbed on silica gel,
as well as air- and light-sensitive, it should not be
allowed to remain on the column any longer than is
necessary to obtain it in a pure enough state for the next
step, and should be protected from bright illumination
as much as possible.
extraction of a solution of 14 in chcl3 in a separatory
funnel with aqueous na2s2o4 (sodium hydrosulfite) for
a few minutes until the color changed from red to yellow
afforded the alcohol l5 (87%) as a pale greenish-yellow
solid whose 1h nmr spectrum featured a pair of
doublets at delta 6.07 and delta 6.17 for the azepinyl protons,
a broad singlet at delta 6.04 for the proton on n-5, and a
sharp singlet at delta 8.82 for the phenolic proton. the
distinctive upfield shifts of the azepinyl protons, the c-1,
c-3, and c-4 protons, and even the protons of the other
ring in comparison with 14 were fully consistent with
reduction of the quinone to a phenol. treatment of 15
with tert-butylchlorodimethylsilane (tbdmscl) and
et3n in chcl3 (room temperature, 4 h) afforded the
protected ether 16 (71%). this selective o-silylation step
was critical in that it prevented reoxidation and also
made it possible to selectively alkylate n-5 without
o-alkylating the phenol.
initial attempts to condense 16 with 2,4-diamino-6bromomethylpteridine as in our earlier synthesis of 6
were unpromising, and we therefore turned our attention to the versatile synthon 2-amino-3-cyano-5-chloromethylpyrazine (17),28 with which we already had
some experience in the synthesis of 2,4-diamino-6-

arylaminomethylpteridines with bulky aryl substituents.29 when 16 and 17 were stirred in the presence of
k2co3 in mecn at room temperature for 72 h the
desired amino nitrile 18 was isolated in 43% yield as a
light-yellow powder after silica gel flash chromatography (4:1 chcl3-meoh). notably, all the protons of the
dibenzazepine ring system in 18 were shifted upfield
relative to 15 and 16, suggesting that the n-5 substituent has a pronounced effect on the magnetic ring current
of the entire tricyclic system.
although we had originally thought that heating 18
with guanidine in refluxing etoh would result in ring
closure without loss of the o-tbdms group, we were
pleasantly surprised to find that under the conditions
used for this reaction (refluxing etoh, 24 h) the
protecting group was removed, presumably by the
naoet used to convert guanidine hydrochloride to the
free base. after chromatography on silica gel (85:15
chcl3-meoh), the deprotected ring closure product 7
was obtained in 60% yield as a light-yellow powder.
that the desired annulation product had formed with
concomitant loss of the o-protecting group was confirmed by the 1h nmr spectrum, which contained a
singlet at delta 8.66, which is characteristic for the c-7
proton in 6-substituted 2,4-diaminopteridines, but no
trace of a singlet at ca. delta 0.1 for the tbdms group,
which had been prominently visible in the spectra of
16 and 18.
o-alkylation of 7 was typically performed (except in
one case as discussed below) in a one-pot operation in
which freshly prepared naoet was dissolved in dry
dmso under an argon atmosphere, the phenol was then
added, and after 30 min to allow the na salt to form, a
10% molar excess of a bromo ester was added. the
reaction mixture was left to stir overnight under argon,
the ester group was cleaved directly with aqueous
naoh, and the deprotected product was isolated in
analytically pure form by two-stage chromatography,
initially on dowex 50w-x2 (h2o, then 1.5% nh4oh
to elute the product as an ammonium salt) and then on
silica gel (3% acoh in 4:1 chcl3-meoh to elute the
product as the free acid). in the case of the 2â€²-o-(2carboxyethyl) analogue 9, attempted alkylation of the
anion of 7 with ethyl 3-bromopropanoate led to almost
none of the desired ester, presumably reflecting facile
base-catalyzed beta-elimination to methyl acrylate. to
circumvent this problem, alkylation of the anion of 7

2478

journal of medicinal chemistry, 2004, vol. 47, no. 10

rosowsky et al.

table 1. inhibition of p. carinii, t, gondii, m. avium, and rat liver dhfr by n-[(2,4-diaminopteridin-6-yl)methyl]dibenz[b,f]azepine
derivatives
ic50 (nm)a

selectivity index (si)b

compd

p. carinii

t. gondii

m. avium

rat liver

p. carinii

t. gondii

m. avium

6c
7
8
9
10
11
12
tmpf
ptxg
tmxh

79 (58-110)
31 (28-35)
21 (18-25)
24 (19-29)
1.1d (0.92-1.3)
11 (9.8-12)
1.0e (0.88-1.2)
13000 (10000-16000)
13 (9.0-17)
47 (34-66)

39 (32-47)
26 (23-30)
17 (12-24)
28 (25-30)
9.9 (8.9-11)
21(20-23)
22 (18-27)
2800 (2400-3300)
4.3 (4.0-4.6)
16 (8-30)

12 (9.1-17)
1.3 (1.2-1.4)
8.2 (6.2-11)
4.0 (3.6-4.4)
2.0 (1.7-2.3)
7.2 (6.5-8.0)
0.75 (0.55-1.0)
300 (260-350)
0.61 (0.53-0.70)
1.5 (1.3-1.7)

3000 (2500-3600)
41 (370-440)
280 (250-300)
1100 (1100-1200)
1500d (1100-1800)
1300 (1100-1500)
580e (500-680)
180000 (160000-210000)
3.3 (2.9-3.9)
8.0 (7.0-9.2)

38 (23-62)
13 (11-16)
13 (10-17)
46 (12-63)
1300 (850-2000)d
120 (80-150)
560 (420-780)e
14 (10-20)
0.26 (0.17-0.42)
0.17 (0.11-0.27)

77 (53-113)
16 (12-19)
16 (10-25)
39 (37-48)
120 (90-160)
62 (55-65)
26 (13-36)
65 (48-87)
0.76 (0.63-0.97)
0.50 (0.23-1.2)

250 (150-400)
320 (260-370)
34 (23-48)
280 (250-330)
600 (430-820)
180 (140-230)
630 (350-1200)
610 (460-810)
5.4 (4.1-7.2)
5.3 (3.4-7.2)

a numbers in parentheses are 95% confidence intervals, rounded off to two significant figures and based on ic values likewise rounded
50
off to two significant figures. the difference in ic50 between rat liver dhfr and each of the parasite enzymes was determined to be
statistically significant at p < 0.01 (welchâ€™s t-test). b si ) ic50(rat liver dhfr)/ic50(pc, tg, or ma dhfr). numbers in parentheses are
95% confidence intervals rounded off to two figures and represent a range calculated by dividing the lower end of the 95% confidence
interval for the ic50 against rat liver dhfr by the upper end of the 95% confidence interval for the ic50 against pc, tg, or ma dhfr;
si values of <1.0 signify lack of selectivity. c in our preliminary report on 6 (see ref 22), the ic50 values against pc, tg, ma, and rat liver
dhfr were listed as 210, 43, 12, and 4400 nm, respectively (with no 95% confidence limits provided). d in a separate experiment on a
different day, the ic50 (nm) and si values of 10 against pc dhfr, with 95% confidence intervals in parentheses, were pc, 1.1 (0.99-1.2),
and 1100 (830-1200). e in a separate experiment on a different day, the ic50 (nm) and si values of 12, with 95% confidence intervals in
parentheses), were 1.1 (0.90-1.0) and 430 (320-710). f tmp ) trimethoprim, 2,4-diamino-5-(3â€²,4â€²,5â€²-trimethoxybenzyl)pyrimidine; data
from ref 11b. g ptx )  xxxd2968xxx , 2,4-diamino-5-methyl-6-(2â€²,5â€²-dimethoxybenzyl) xxxd3047xxx [2,3-d]pyrimidine; data from ref 11b. h tmx )
 xxxd3442xxx , 2,4-diamino-5-methyl-6-(3â€²,4â€²,5â€²-trimethoxyanilinomethyl)quinazoline.

was performed with 3-bromopropanoic acid in the presence of an extra 1 equiv of base. the superiority of
3-bromopropanoic acid over methyl 3-bromopropanoate
in the o-alkylation of a phenolic oh group is wellknown, and was noted, for example, by kuyper and coworkers30 during their synthesis of the trimethoprim
analogue 2,4-diamino-5-[3â€²-o-(3-carboxyethoxy)-4â€²,5â€²dimethoxybenzyl]pyrimidine. interestingly, when the
crude acid 9 was eluted from a dowex 50w-x2 (h+
form) column with 1.5% nh4oh, and the eluate was
acidified with hcl (instead of acoh), freeze-dried, and
finally chromatographed on silica gel using chcl3meoh as the eluent, the isolated product gave a tlc
spot with a much higher rf than would be expected from
an acid, and its elemental analysis as well as 1h nmr
and mass spectra confirmed that it was in fact the
methyl ester 9a. saponification of 9a, followed by ionexchange chromatography and acidification of the nh4oh eluate with hcl, yielded the hydrated sesquihydrochloride salt of 9 with an overall 22% yield starting from
7.
enzyme inhibition
the ability of 8-12 and their phenolic precursor 7 to
inhibit reduction of dihydrofolate by pc, tg, ma, and
rat dhfr in the presence of nadph was determined
spectrophotometrically at 340 nm according to the
standardized assays we have used previously.22,31,32
 xxxd543xxx  was tested as a sesquihydrochloride salt,
the form in which it was obtained after purification, but
this was not expected to affect the results since the ph
of the dhfr assay medium was buffered to ph 7.4. the
ic50 value and selectivity index (si), together with the
corresponding 95% confidence intervals, are shown for
each compound in table 1. also included for comparison
are the ic50 and si values for trimethoprim and  xxxd2968xxx  as prototypical examples of dhfr inhibitors that
can be viewed as weak but selective (trimethoprim)
versus potent but nonselective ( xxxd2968xxx ).
pneumocystis carinii dhfr. the ic50 of the 2â€²hydroxy derivative 7 against pc dhfr was approxi-

mately 2-fold lower than that of 6. however, because
potency against rat dhfr increased to an even greater
degree, this modification was unfavorable for selectivity
against the pc enzyme. replacement of the 2â€²-hydroxy
group by a 2â€²-o-carboxymethyl or 2â€²-o-(2-carboxyethyl)
group as in 8 and 9, respectively, did not improve
inhibition of pc dhfr in comparison with 7. in contrast,
the 2â€²-o-(3-carboxypropyl analogue 10 had an ic50 of
1.1 nm against pc dhfr as compared with 1500 nm
against the rat enzyme, corresponding to a selectivity
index of 1300, a value 34 times greater than that of 6,
and among the highest we have observed in our work
on pc dhfr inhibitors to date. interestingly, the longer
homologue 11, with four ch2 groups in the side chain,
was less potent and also less selective than 10, indicating that potency and selectivity diminish when the
number of ch2 groups in the side chain exceeds three.
this contrasted with our earlier findings on 2,4-diamino[2â€²-methoxy-5â€²-(omega-carboxyalkyloxy)benzyl]pyrimidines,
where potency and selectivity against pc dhfr was
greater with four rather than three ch2 groups in the
side chain.11a this difference can probably be explained
on the basis that the larger diaminoheterocyclic moiety
in 7 projects the cooh group somewhat differently into
the binding pocket of the enzyme. of interest, finally,
was the considerable potency and selectivity of the 2â€²o-(4-carboxybenzyl) analogue 12, whose ic50 of 1.0 nm
equaled that of 10 although its selectivity index of 560
was somewhat lower. this finding suggests that replacement of the ch2ch2ch2 chain by a benzyl group
is allowed, and that this type of structural modification
may be worth exploring (e.g., by making the corresponding phenethyl derivative or moving the carboxyl
group to the meta or ortho position).
trimethoprim has been reported by workers at hoffman-laroche to inhibit pc and human dhfr with ic50
values of 46 and 900 Âµm, respectively, corresponding
to a selectivity index of 20.33 by contrast, in comparisons
of the activity of trimethoprim against pc and rat dhfr
under standardized conditions, the average si value
observed by one of us (s.f.q.) over a period of ap-

 xxxg631xxx  inhibitors

journal of medicinal chemistry, 2004, vol. 47, no. 10 2479

proximately 10 years has been only 14 (95% confidence
interval 10-20) (table 1). in assays comparing pc and
human dhfr the ic50 and selectivity values of the
newer trimethoprim analogue 2,4-diamino-6-(3â€²,5â€²-diethoxy-4â€²-pyrrolobenzyl)pyrimidine (epiroprim, 19) were

900 and 600 000 (i.e., a somewhat higher selectivity
index of 670). more recently, piper and co-workers13a
reported a pteridine derivative, 21, with ic50 values of
770 nm against tg dhfr and 250 000 nm against rat
dhfr (si ) 320), and a  xxxd3047xxx [2,3-d]pyrimidine derivative, 22, whose corresponding ic50 values were 7.9 and
770 nm (si ) 98) thus, 22 was more potent but less
selective than 21. compound 10 (ic50 ) 9.9 nm) was
78-fold more potent than 21 but only 7-fold more potent
than 22, and its selectivity index appeared to fall
between the two of them. however, because 95% confidence intervals were not reported for 21 and 22, the
differences in selectivity among the three compounds
should probably be viewed with caution. regardless of
whether the selectivity difference between 10 and 21
withstands statistical analysis, it seems clear that 10
is one of the most potent lipophilic 2,4-diamino-6substituted pteridines we have encountered until now.

reported by the hoffman-laroche group to be 3000 nm
and 200, respectively,33 whereas in assays comparing
pc and rat dhfr these values were found to be 2600
nm and 160.34 thus, the potency and selectivity 10 as
an inhibitor of pc dhfr appear to be superior to those
of both trimethoprim and epiroprim.
interestingly, when the selectivities of several antifolates, including 6 and trimethoprim, for pc versus
either rat or human dhfr were compared, a considerable variation in the species selectivity pattern was
observed.35,36 while the si of trimethoprim for pc versus
human dhfr was ca. 50% higher than the si for pc
versus rat dhfr, the si of 6 for pc versus rat and
human enzyme was virtually the same. in striking
contrast, the si of the triazenyl pyrimethamine analogue tab (20)14a,b for pc versus human dhfr was 350fold higher than the si for pc versus rat dhfr.

toxoplasma gondii dhfr. the 2â€²-hydroxy analogue 7 was nearly as potent as 6 against tg dhfr,
but was a 73-fold better inhibitor of the rat enzyme. as
a result, 7 was less selective than 6. the 2â€²-o-carboxymethyl analogue 8 was very similar to 7 in terms of both
potency and selectivity. in the case of the 2â€²-o-(2carboxyethyl) and 2â€²-o-(4-carboxybutyl) analogues 9 and
11 there was a small improvement in selectivity, but
this reflected a decrease in the inhibition of the rat
enzyme rather than an increase in inhibition of the tg
enzyme. on the other hand, the selectivity of 2â€²-o-(3carboxypropyl) analogue 10 was  xxxd102xxx  than that
of the other congeners, apparently as a result of the
combined effect of increased inhibition of tg dhfr and
decreased inhibition of rat dhfr. although 10 was the
most potent and selective inhibitor of tg dhfr among
the compounds in this group, its selectivity was 10 times
lower against this enzyme than against pc dhfr,
indicating that whatever differences in the 3d structure
of the active site may exist between rat and tg dhfr,
these differences are not exploited as effectively by this
2â€²-modification as the corresponding differences between
the rat and pc enzymes.
in assays comparing tg and human dhfr, the
hoffman-laroche group found trimethoprim to have
ic50 values of 2700 nm and 900 000 nm, i.e., a selectivity index of 330.33 for epiroprim (19), these values were

mycobacterium avium dhfr. as shown in table
1, the 2â€²-hydroxy group in 7 resulted in a one-log
increase in potency against m. avium dhfr relative
to 6, but because this was nearly matched by a 73-fold
increase in potency against the rat enzyme, the selectivity index did not change appreciably. with the introduction of a 2â€²-o-(carboxymethyl) group, as in 8, there was
a slight increase in potency against ma dhfr relative
to 6. however, because this was accompanied by a larger
11-fold decrease in potency against the rat enzyme, this
modification appeared to have a detrimental effect on
selectivity, just as it did in the case of the pc and tg
enzymes. the 2â€²-o-(2-carboxyethyl) analogue 9 was
8-fold more selective than 8, and this appeared to be
due to a combination of increased inhibition of the ma
enzyme and decreased inhibition of the rat enzyme.
elongation of the side chain to three ch2 groups, as in
10, elicited a 4-fold increase in potency and an 18-fold
increase in selectivity relative to 8. however, when one
more ch2 group was introduced, as in 11, potency and
selectivity both decreased, recalling the pattern observed with 11 versus 10 against pc and tg dhfr.
replacement of the 2â€²-o-(3-carboxypropyl) group of 10
by a 2â€²-o-(4-carboxybenzyl) group, as in 12, led to a
modest increase in potency against the ma enzyme, but
because this was accompanied by a similar increase in
potency against the rat enzyme there was essentially
no change in selectivity, with both compounds giving
an si value of ca. 600. the ic50 of 12 against ma dhfr
was several times lower than the reported values for
2,4-diamino-5-[2â€²-methoxy-5â€²-o-(4-carboxybutyl)oxybenzyl]pyrimidine (23, ic50 ) 5.8 nm)11a and 2,4-diamino5-[2â€²-methoxy-5â€²-(4-carboxy-1-butynyl)benzyl]pyrimidine (24, ic50 ) 4.4 nm),11b the most potent inhibitors
of this enzyme we had encountered up to that point.
apart from its excellent potency, the selectivity of 12
for ma versus rat dhfr (si ) 630) was of the same
order as that of 23 (si ) 660) and 24 (si ) 910). it
should be noted, however, that 10 and 12 are neither

2480

journal of medicinal chemistry, 2004, vol. 47, no. 10

rosowsky et al.

figure 1. structures of the ternary complexes of 10 and nadph with p. carinii (panel a) and human (panel b) dhfr after 0.5
ns dynamic simulation. model produced using the pymol molecular graphics system (delano scientific, san carlos, ca).
hydrogen atoms are omitted for clarity.

the most potent nor the most selective ma dhfr
inhibitors thus far described in the literature. for
example, workers at hoffman-laroche have reported
that epiroprim (19) has an ic50 of 4.1 nm against ma
dhfr and a prodigious selectivity index of >14 000
relative to the human enzyme.33 a second compound,
2,4-diamino-5-methyl-6-[(3â€²,5â€²-di-n-propyloxyanilino)methyl] xxxd3047xxx [2,3-d]pyrimidine (25), which may be
viewed as an analogue of both  xxxd2968xxx  (heterocyclic
system) and  xxxd3442xxx  (bridge), was reported by
suling and co-workers13b to have an ic50 of only 0.19
nm against ma dhfr, with a selectivity index of 7300
relative to the human enzyme. several other compounds
in their series had ic50 values of <1.0 nm and selectivities of >1000.37 since the si of 6 for pc versus human
dhfr has been found to be comparable to its si for pc
versus rat dhfr,35 and compounds 10 and 12 have the
same basic structure as 6, their si for ma versus human
dhfr is not likely to differ much from the values in
table 1. thus, where ma dhfr inhibition is concerned,
these compounds are of interest only insofar as they are
the best pteridine derivatives in our work to date.
however, on the basis of the results obtained by the
southern research institute groups,13b analogues of 25

with a 2â€²-(3-carboxypropyl)oxy moiety in the side chain
would be of potential interest. given the promising in
vitrodatarecentlyreportedforthecombinationepiroprimdapsone against mycobacterium leprae and mycobacterium ulcerans,38 potent and selective dhfr inhibitors
of the type reported in this paper could be considered
for testing against non-aids associated mycobacteria.

modeling studies
to better understand the reason for the remarkable
selectivity of binding of 10 to pc dhfr, we used sybyl
6.939 on a silicon graphics octane 2 workstation to
perform a computational simulation of the 3d structure
of the ternary complex with nadph. the starting
coordinates for the simulation were generated by leastsquares superposition of the pteridine moiety of 10 onto
the previously solved crystal structure of the ternary
complex with pc and human dhfr with 6 as the bound
ligand.22,23 the complex was solvated in a box of water,
but the current force field did not take polarizable
parameters into account. in considering such a model,
it is important to remember that molecular dynamics
can only regarded as snapshots of low energy states,
and that a global minimum is unlikely to be derived by
this method even after extensive cycles of dynamics
simulation and energy minimization.
the simulated structure of the ternary complex of 10
and nadph with pc and human dhfr is presented
in figure 1, which depicts a view looking down into the
cleft of the enzyme where the diaminopyrimidine moiety
lies buried. based on the finding that every residue in
the active site of human and rat dhfr is conserved,35
the assumption was made that the 3d structure of the
ternary complex of 10 would probably be very similar,
if not identical, with both enzymes. visible in both panel
a and panel b is the nonplanar dibenzazepine ring
system and its rotationally twisted orientation with
respect to the diaminopteridine moiety, already noted
in the case of 6.23 important active site residues located
within a 4.5 Ã¥ radius from the inhibitor are denoted
according to standard amino acid nomenclature. the
inhibitor is anchored to both enzymes through the usual
interaction of protonated n1 and the 2-amino group of
the pteridine moiety with  xxxd2431xxx  (e32 in the pc
enzyme; e30 in the human enzyme). the n4 amino
group lies within h-bonding distance of backbone amide
oxygens in i10 and i123 of pc dhfr and i7 and v115
of human dhfr (omitted from the figure). the inhibitor

 xxxg631xxx  inhibitors

journal of medicinal chemistry, 2004, vol. 47, no. 10 2481

lies in a hydrophobic channel that allows for van der
waals interaction of the dibenzazepine moiety with
phenylalanine (f69, 5.75 Ã¥ to the center of the a-ring,40
offset stacking), proline (p66, 3.77 Ã¥ from the center of
the b-ring), and leucine (l25, 3.80 Ã¥ to the center of
c-ring) in the case of the pc enzyme, and with phenylalanine (f31, 4.65 Ã¥ to the center of the a-ring, offset
stacking), and proline (p61, 4.14 Ã¥ to the center of the
b-ring) in the case of the human enzyme. the offset
stacking interaction of f69 with one face of the a-ring
in the pc enzyme is not possible in the human enzyme,
whose corresponding residue is asparagine (n64). instead there is in the human ternary complex an offset
stacking interaction of f31 with the opposite face of the
a-ring. probably of greatest importance in terms of
species-selective dhfr inhibition, however, is the ionic
or h-bonded interaction of the terminal cooh group
of 10 with the -amino group of a lysine residue ( xxxd904xxx )
in pc dhfr, which is not possible in the case of the
human enzyme because the homologous residue is a
neutral glutamine (q35). although it would possible in
principle for the conh2 side chain of q35 to engage in
an ion-dipole interaction with this cooh group, the
contribution of ion-dipole interactions in molecular
recognition is considered to be weaker than ionic
interactions.41 thus ion-dipole interaction between the
cooh group and q35 in human dhfr is unlikely to
produce as much binding energy as ionic interaction of
the cooh group with the positively charged amino
group of  xxxd904xxx  in pc dhfr.
the cooh group of 10 appears to lie within approximately 3 Ã¥ of the arginine side chain in both the
pc (r75) and the human (r70) enzyme. the energyminimized distances between the o2 and o3 atoms of
the cooh group and the -nh2 group of  xxxd904xxx  are 3.19
and 3.09 Ã¥. the distances between these oxygens and
the n2 and n1 atoms, respectively, of the guanidine
group are 4.02 and 2.99 Ã¥ for pc dhfr, and 2.96 and
2.97 Ã¥ for human dhfr. since the arginine residue is
conserved in both enzymes, it presumably cannot account for the observed preferential inhibition of the pc
enzyme. it is worth noting that similar interactions of
the lysine and arginine residues in pc and human
dhfr with the side-chain cooh group of 24 were
predicted from modeling studies42a and subsequently
confirmed by crystallography.42b crystallographic analysis of the 3d structure of the ternary complex of 10 with
nadph and pc dhfr is currently being performed in
dr. vivian codyâ€™s laboratory, and the results will be
reported in due course.

dhfr, with ic50 values of 9.9 and 2.0 nm and si values
of 120 and 600, respectively. thus it was somewhat less
potent and selective against these enzymes than against
pc dhfr. 2,4-diamino-6-[2â€²-o-(4-carboxybenzyl)oxydibenz[b,f]azepine (12) was as potent as 10 but somewhat less selective against pc and tg dhfr and was
approximately as potent and selective against ma
dhfr. these compounds are the most active pteridines
we have tested to date against these enzymes and may
be viewed as promising leads for further investigation.
especially attractive would be the possibility of using a
compound such as 10 without coadministration of a
sulfa drug to boost efficacy or  xxxd2462xxx  to prevent host
toxicity.

conclusion
in summary, six 2,4-diamino-6-(dibenz[b,f]azepin-5yl)methylpteridine analogues in which a 2â€²-(omega-carboxyalkyloxy) or a 2â€²-(4-carboxybenzyloxy) substituent has
been introduced in order to afford water solubility and
enhance dhfr affinity were synthesized and tested as
inhibitors of pc, tg, ma, and rat dhfr. 2,4diamino-6-[2â€²-o-(3â€²-carboxypropyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (10) was an exceptionally potent and selective inhibitor of the pc enzyme, with an
ic50 of 1.1 nm and a selectivity of 1300 for the pc
enzyme versus the rat enzyme (ic50 ) 1500 nm). this
compound was likewise a good inhibitor of tg and ma

experimental section
ir spectra in kbr disks were obtained on a perkin-elmer
model 781 double-beam recording spectrophotometer; only
peaks with wavenumbers greater than 1200 cm-1 are reported.
1
h nmr spectra were recorded in dmso-d6 solution at 200
mhz on a varian vx200 instrument or at 400 mhz on a
varian vx400 instrument. quantitative uv spectra were
determined in 4:1 mecn-h2o (c ) 5 Ã— 10-4 m) on a perkinelmer 35 uv/visible instrument. low-resolution ms data were
provided by the molecular biology core facility of the danafarber cancer institute. tlc was on whatman mk6f silica
gel-coated microscope slides, with spots being visualized under
254 nm uv illumination. preparative tlc was on silica gelcoated glass plates (aldrich, 1000 Âµm layer, 20 Ã— 20 cm, with
fluorescent indicator). column chromatography was on silica
gel (â€˜flashâ€™ grade, baker 7024, 40 Âµm particle size). chemicals
and â€˜sure-sealâ€™ solvents were purchased from aldrich (milwaukee, wi). melting points were determined in pyrex capillary tubes in a mel-temp apparatus (laboratory devices, inc.,
cambridge, ma) and are not corrected. elemental analyses
were performed by qti laboratories, whitehouse, nj, or
robertson laboratories, madison, nj, and were within (0.4
of theoretical values unless otherwise noted. as has been our
previous experience with n-heterocyclic compounds of the type
synthesized in this work, the analytical data were consistent
with varying amounts of residual acoh, meoh, chcl3, or h2o
in the analytical samples, which were dried in vacuo, but only
at the ambient temperature of the laboratory. the presence
of residual solvent was confirmed wherever possible by 1h
nmr. although chlorine analysis was not performed on
compounds 8 and 12, their assigned elemental composition was
supported in both cases by the presence of the correct molecular ion (mh+) in the mass spectrum.
dibenz[b,f]azepin-2-one (14). a solution (kso3)2no (fremyâ€™s salt, 2.5 g, 9.32 mmol) was added in small portions to a
solution of na2hpo2 (1.8 g, 12.7 mmol) in double-distilled h2o
(95 ml), and the ph was adjusted to exactly 7.22 with a meter.
small portions of the purple solution were then added to a
vigorously stirred solution of 13 (0.55 g, 2.76 mmol) in acetone
(60 ml), and after 10 min the mixture was filtered and left in
the refrigerator overnight. after concentration to a small
volume by rotary evaporation under a stream of argon (while
keeping the water bath at room temperature for best results),
the product was extracted into et2o (500 ml). the solvent was
evaporated and the residue chromatographed on silica gel
using a 4:1 mixture of hexanes and etoac as the eluent. the
first fraction was unchanged 13 which could be pooled from
several experiments and recycled (56 mg, ca. 10% recovery).
the second fraction, a yellow solid, was determined to be
acridine-9-carboxaldehyde (70 mg); 1h nmr (cdcl3) delta 11.5
(chdo). the third fraction, a deep-red microcrystalline
powder after recrystallization from et2o, was the desired
iminoquinone 14 (0.44 g, 77%); mp 133-134 Â°c (lit.,25 135136 Â°c); 1h nmr: delta 6.69 (d, j ) 2.4 hz, 1h, h1), 6.95 (dd, j
) 12.8 hz, j ) 2.4 hz, 1h, h3), 7.01 (d, j ) 12.8 hz, 1h, h4),
7.20 (d, j ) 11.8 hz, 1h, h11), 7.57 (d, j ) 11.8 hz, 1h, h10),
7.65-7.92 (complex m, 4h, h6-h9).

2482

journal of medicinal chemistry, 2004, vol. 47, no. 10

rosowsky et al.

2-hydroxy-5h-dibenz[b,f]azepine (15). a solution of 14
(0.3 g, 1.45 mmol) in chcl3 (10 ml) was shaken in a
separatory funnel with freshly prepared solution containing
an excess of na2s2o4 (0.62 g, 3.56 mmol) in h2o (4 ml) until
the color of the organic layer changed from red to yellow. the
aqueous layer was extracted with chcl3 (2 Ã— 10 ml), the
combined organic extracts were dried (na2so4), and the
solvent was evaporated by rotary distillation. recrystallization
of the residue from chcl3 afforded 15 as pale greenish-yellow
crystals (0.26 g, 87%); mp 222-223 Â°c (lit.26 225-226 Â°c); 1h
nmr: delta 6.04 (br s, nh), 6.07 (d, j ) 11.8 hz, 1h, h10 or
h11), 6.16 (d, j ) 11.8 hz, 1h, h10 or h11), 6.23 (d, j ) 2.2
hz, 1h, h1), 6.40 (d, j ) 8.6 hz, j ) 2.2 hz, 1h, h3), 6.48 (d,
j ) 8.6 hz,1h, h4), 6.59-6.70 (complex m, 4h, h6-h9), 8.82
(s, 1h, phenolic oh).
2-(tert-butyldimethylsilyloxy)-5h-dibenz[b,f]azepine
(16). a mixture of 15 (1.4 g, 6.7 mmol), tert-butylchlorodimethylsilane (2.5 g, 19 mmol), and et3n (1 ml) in dry chcl3
(80 ml) was stirred at room temperature for 48 h. the solvent
and excess silane were removed by rotary evaporation, and
the residue was chromatographed on silica gel with a 4:1
mixture of hexanes and etoac to obtain 14 as a yellow solid
(1.55 g, 71%); mp 188-189 Â°c; 1h nmr: delta 0.13 (6h, sime2,
0.92 (s, 9h, sibu-t), 6.06 (broad s, nh), 6.08 (d, j ) 12.2 hz,
1h, h10 or h11), 6.10 (d, j ) 12.2 hz, 1h, h10 or h11), 6.29
(d, j ) 2.2 hz, 1h, h1), 6.50 (q, j ) 8.0 hz, 1h, h3), 6.58 (d,
j ) 8.0 hz, 1h, h4), 6.63-6.96 (complex m, 4h, h6-h9). anal.
(c20h25nosi) c, h, n; si, calcd 8.68, found 9.27.
2-amino-3-cyano-5-[2â€²-(tert-butyldimethylsilyl)oxydibenz[b,f]azepin-5-yl]pyrazine (18). a suspension of 16
(1.62 g, 5 mmol) in anhydrous mecn (50 ml) was treated with
17 (0.85 g, 5 mmol) and powdered k2co3 (1.4 g, 10 mmol),
and the reaction mixture was stirred at room temperature for
72 h. the salts were filtered off, the filter cake was extracted
with hot etoac, and the combined organic solvents were
removed by rotary evaporation. flash chromatography of the
amber-colored residue on silica gel using a 4:1 mixture of
chcl3 and meoh as the eluent afforded 15 as a light-yellow
powder (0.95 g, 43%) mp 204-205 Â°c; 1h nmr: delta 0.11 (s, 6h,
sime2), 0.89 (s, 9h, sibu-t), 4.85 (s, 1h, nch2), 6.60 (br s,
nh), 6.72 (d, j ) 8.6 hz, 1h, h3â€²), 6.78 (s, 1h, h1â€²), 6.83 (d,
j ) 8.6 hz, 1h, h4â€²), 6.95 (d. j ) 8.4 hz, 1h, h10â€² or h11â€²),
6.98 (d, j ) 8.4 hz, 1h, h10â€² or h11â€²), 7.13-7.78 (complex m,
4h, h6â€²-h9â€²), 7.43 (br s, nh2), 8.20 (s, 1h, pyrazine h6).
2,4-diamino-6-(2â€²-hydroxydibenz[b,f]azepin-5-yl)methylpteridine (7). clean na metal (0.12 g, 5 mmol) was
dissolved in absolute etoh (30 ml), and guanidine hydrochloride (0.48 g, 5 mmol) was added in a single portion. after
5 min of stirring at room temperature, amino nitrile 18 (0.82
g, 1.8 mmol) was added and the mixture was refluxed for 24
h. the solvent was removed by rotary evaporation, and the
residue was triturated with h2o (20 ml) and filtered. the
product was dissolved in meoh (20 ml) and the solution
evaporated onto silica gel (1 g). the dried silica gel was placed
on top of a silica gel column which was eluted 85:15 chcl3meoh to obtain 7 as a yellow solid (0.44 g, 60%); mp 251 Â°c
dec; ms: found m/e 384.1, calcd 384.2 (mh+); ir: nu 3460, 3400,
1620, 1450, 1360, 1210 cm-1; uv: lambdamax 373 nm ( 8277); 1h
nmr: delta 5.03 (s, 2h, nch2), 6.51 (d, j ) 2.0 hz, 1h, h1â€²),
6.62 (q, j ) 8.8 hz, j ) 2.0 hz, 1h, h3â€²), 6.79 (d, j ) 11.4 hz,
1h, h10â€² or h11â€²), 6.83 (d, j ) 11.4 hz, 1h, h10â€² or h11â€²),
6.97 (d, j ) 8.8 hz, 1h, h4â€²), 7.11-7.23 (complex m, 4h, h6â€²h9â€²), 7.49 (br s, nh2), 7.60 (br s, 1h, nh2), 8.66 (s, 1h,
pteridine h7), 9.18 (br s,1h, phenolic oh). anal. (c21h17n7oâ€š
0.7h2o) c, h, n.
2,4-diamino-6-[2â€²-(omega-carboxyalkyl)oxy- or 2â€²-(4-carboxybenzyl)oxydibenz[b,f]azepin-6-yl]methylpteridines (general procedure). clean metallic na (12 mg, 0.5 mmol) was
dissolved in absolute etoh (1 ml), the solvent was evaporated
under reduced pressure, and the naoet was redissolved in
anhydrous dmso (1.5 ml). the phenol 7 (190 mg, 0.5 mmol)
was then added, the reaction mixture containing the na salt
of 7 was stirred at room temperature for 30 min, the appropriate bromo ester (0.6 mmol) was added in a single portion, and

the flask was fitted with a balloon of dry argon. tlc (silica
gel, 4:1 chcl3-meoh) easily revealed gradual loss of the spot
corresponding to the starting material and its replacement by
a faster-moving spot. the reaction was allowed to proceed
overnight under argon, and the product was immediately
saponified in situ by adding 2 n naoh (1.5 ml) followed by
h2o to a final volume of 60 ml. any insoluble material
remaining at this point was filtered off, and after addition of
a small volume of dilute ammonia, the clear solution was
applied onto a column of dowex 50w-x2 (h+ form, 2 cm Ã—
20 cm). the column was washed with h2o until the eluate
was neutral and uv-transparent, and then with 1.5% nh4oh to remove the product as a mixture of sodium and
ammonium salts. appropriately pooled eluates were concentrated to a small volume (or to dryness) by rotary evaporation
followed by lyophilization. the solid was taken up in the
minimum volume of meoh required to dissolve it, silica gel
(0.5 g) was added, and the mixture was taken to dryness by
rotary evaporation. the silica gel with preadsorbed product
was loaded onto a silica gel column packed in chcl3, and the
product was eluted with 3% acoh in 4:1 chcl3-meoh.
purification was monitored by tlc, and appropriately pooled
fractions containing the product were evaporated and dried
in vacuo in a lyophilization apparatus. compounds 8, 10, and
11 were obtained in this procedure, whereas 9 was prepared
by a slight variation of the method detailed below.
2,4-diamino-6-[2â€²-o-(carboxymethyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (8): tan solid (101 mg, 35%);
mp 223 Â°c dec; ms: found m/e 441.9, calcd 442.2 (mh+); ir:
nu 3420, 3200, 1700, 1630, 1500, 1480, 1450, 1380, 1220, 1070
cm-1; uv: lambdamax 353 nm ( 5785); 1h nmr: delta 4.51 (s 2h, ch2o),
5.06 (s, 2h, ch2n), 6.57 (br s, nh2), 6.69 (d, j ) 2.8 hz, 1h,
h1â€²), 6.79 (q, j ) 8.9 hz, j ) 2.8 hz, h3â€²), 6.83 (d, j ) 6.2 hz,
1h, h10â€² or h11â€²), 6.84 (d, j ) 6.2 hz, 1h, h10â€² or h11â€²), 6.90
(d, j ) 8.9 hz, 1h, h4â€²), 6.90-7.24 (m, complex m, h6â€²-h9â€²),
7.52 (br s, nh2), 8.67 (s, 1h, pteridine h7), 12.22 (br s, cooh).
anal. (c23h19n7o3. meohâ€š0.4chcl3) c, h, n.
2,4-diamino-6-[2â€²-o-(2-carboxyethyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (9). clean metallic na (24 mg,
1.0 mmol) was dissolved in absolute etoh (2 ml), the solvent
was evaporated under reduced pressure, and the residue was
taken up in dry dmso (1.5 ml). the phenol 7 (190 mg, 0.5
mmol) was then added, and the mixture was stirred at room
temperature for 30 min, followed by addition of 3-bromopropanoic acid (79 mg, 0.5 mmol) in a single portion. after being
stirred overnight under dry argon, the mixture was evaporated
under reduced pressure and the residue was dissolved in h2o
(60 ml) and 2 n naoh (1 ml). the clear solution was applied
onto a column of dowex 50w-x2 (h+ form, 2 cm Ã— 20 cm),
and the column was washed with h2o until the eluate was
neutral and uv-transparent and then with 1.5% nh4oh to
elute the product. appropriately pooled fractions of the latter
eluate were acidified to ph 2 with 10% hcl, followed by rotary
evaporation and freeze-drying. the resulting solid was taken
up in meoh (10 ml), chromatography-grade silica gel (0.5 g)
was added to the solution, and the mixture was evaporated to
dryness. the silica gel with preadsorbed product was then
placed on a column of silica gel which had been prepacked with
chcl3. the column was eluted with 4:1 chcl3-meoh as in
the preceding experiment, and the major band was collected
and evaporated to a brown solid which proved to be the methyl
ester of 9; 88 mg, 38%); mp 240-241 Â°c dec; ms: found m/e
470.0, calcd 470.5 (mh+); 1h nmr: delta 2.72 (t, 2h, j ) 6.2 hz,
ch2cooh), 3.59 (s, 3h, ome), 4.10 (t, 2h, j ) 6.2 hz, och2),
5.07 (s, 2h, nch2), 6.63 (d, 1h, j ) 7.0 hz, h10â€² or h11â€²),
6.74 (q, j ) 8.9 hz, j ) 2.8 hz, h3â€²), 6.85 (d, 1h, j ) 7.0 hz,
h10â€² or h11â€²), 6.98 (d, 1h, j ) 8.9 hz, h4â€²), 6.70-7.24
(complex m, 4h, h6â€²-h9â€²), 7.56 (br s, nh2), 7.65 (br s, nh2),
8.67 (s, 1h, pteridine h7). anal. (c25h23n7o3â€šmeoh). c,h,n.
saponification of 9 was carried out by stirring it 2 n naoh
(1.5 ml) at room temperature while monitoring the reaction
by tlc (silica gel, 85:15 chcl3-meoh). a clear solution
gradually formed, and the fast-moving ester spot was replaced
by a slow-moving spot where the acid was expected to be. after

 xxxg631xxx  inhibitors

journal of medicinal chemistry, 2004, vol. 47, no. 10 2483

15 min, the solution was diluted with h2o to a final volume
of 40 ml and applied to the top of a dowex 50w-x2 column
(h+ form, 2 cm, 20 cm). the column was eluted with h2o until
the eluate was neutral and then with 1.5% nh4oh. appropriately pooled fractions of the nh4oh eluate were acidified
to ph 1 with 10% hcl followed by the same the workup as
above afforded a beige solid (51 mg, 22% based on 7); mp 242
Â°c dec); ms: m/e 455.9, calcd 455.2 (mh+, free acid); ir (kbr)
nu 3420, 3200, 1615, 1550, 1480, 1450, 1380, 1360, 1285, 1200
cm-1; uv: lambdamax (h2o) 350 nm ( 7630); lambdamax (mecn) 383 nm (
7246); nmr: delta 2.64 (t, 2h, j ) 6.0 hz, ch2cooh), 4.07 (t,
2h, och2), 5.04 (s, 2h, nch2), 6.63 (d, 1h, j ) 2.8 hz, h1â€²),
6.74 (q, 1h, j ) 8.9 hz, j ) 2.8 hz, h3â€²), 6.79 (d, 1h, j ) 7.0
hz, h10â€² or h11â€²), 6.80 (d, 1h, j ) 7.0 hz, h10â€² or h11â€²), 6.95
(d, 1h, j ) 8.9 hz, h4â€²), 7.06-7.24 (m, 4h, h6â€²-h9â€²), 7.61
(br s, nh2), 7.69 (br s, nh2), 8.67 (s, 1h, pteridine h7), 12.31
(br s, cooh). anal. (c24h21n7o3â€š1.5hclâ€šh2o) c, h, n.
2,4-diamino-6-[2â€²-o-(3-carboxypropyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (10): tan solid (157 mg, 58%);
mp 236 Â°c dec; ms: found m/e 470.0, calcd 470.2 (mh+); ir:
nu 3440, 3400, 1700, 1630, 1550, 1450, 1380, 1200 cm-1; uv:
lambdamax 363 nm ( 5874); 1h nmr: delta 1.86 (m, 2h, ch2ch2ch2),
2.32 (t, j ) 7.4 hz, 2h, ch2cooh), 3.87 (t, j ) 6.4 hz, 2h,
och2), 5.06 (s, 2h, nch2), 6.56 (br s, nh2), 6.71 (d, j ) 2.6
hz, h1â€²), 6.77 (q, j ) 8.8 hz, j ) 2.6 hz, 1h, h3â€²), 6.84 (d, j
) 6.2 hz, 1h, h10â€² or h11â€²), 6.85 (d, j ) 6.2 hz, 1h, h10â€² or
h11â€²), 7.01 (d, j ) 8.8 hz, 1h, h4â€²), 6.91-7.28 (complex m,
4h, h6â€²-h9â€²), 7.55 (br s, nh2), 8.67 (s, 1h, pteridine h7),
12.01 (br s, cooh). anal. (c25h23n7o3. meohâ€š0.9h2o) c, h,
n.
2,4-diamino-6-[2â€²-o-(4-carboxybutyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (11): tan solid (145 mg, 48%);
mp 232 Â°c dec; ir: nu 3420, 3400, 1620, 1480, 1450, 1200 cm-1;
ms: found m/e 484.1, calcd 484.2 (mh+); uv: lambdamax 375 nm (
5694); 1h nmr: delta 1.60 (m, 4h, och2ch2), 2.23 (t, j ) 6.6
hz, 2h, ch2cooh), 3.84 (t, 2h, j ) 6.0 hz, och2), 5.07 (s,
2h, nch2), 6.58 (br s, nh2), 6.72 (d, j ) 2.8 hz, 1h, h1â€²),
6.77 (q, j ) 8.8 hz, j ) 2.8 hz, 1h, h3â€²), 6.83 (d, j ) 6.2 hz,
1h, h10â€² or h11â€²), 6.84 (d, j ) 6.2 hz, 1h, h10â€² or h11â€²), 7.01
(d, j ) 8.8 hz, 1h, h4â€²), 6.91-7.28 (complex m, 4h, h6â€²-h9â€²),
7.50 (br s, nh2), 8.67 (s, 1h, pteridine h7), 12.00 (br, cooh).
anal. (c26h25n7o3â€š1.2acohâ€š0.5â€š xxxd2400xxx ) c, h, n.
2,4-diamino-6-[2â€²-(4-carboxybenzyl)oxydibenz[b,f]azepin-5-yl]methylpteridine (12): tan solid (95 mg, 32%);
mp 244-245 Â°c; ms: found 518.0, calcd 518.2; uv: lambdamax 368
nm ( 5845); 1h nmr: delta 5.09 (s, 2h, nch2), 6.57 (s, 2h,
och2), 6.84 (d, j ) 7.4 hz, 1h, h10â€² or h11â€²), 6.88 (d, j ) 7.4
hz, 1h, h10â€² or h11â€²), 6.91 (s, 1h, h1â€²), 7.00 (d, j ) 7.6 hz,
1h, h3â€²), 7.10 (d, j ) 7.6 hz, 1h, h4â€²), 7.17-7.24 (complex
m, 4h, h6â€²-h9â€²), 7.49 (d, j ) 8.0 hz, 2h, protons meta to
cooh), 7.51-7.89 (br s, nh2), 7.91 (d, j ) 8.0 hz, 2h, protons
ortho to cooh). 8.68 (s, 1h, pteridine h7), 12.29 (br s, cooh).
anal. (c29h23n7o3â€š0.9meohâ€š0.4chcl3) c, h; n, calcd 16.08,
found 16.50.
 xxxg631xxx  inhibition. ic50 values for
inhibition of pc and rat dhfr were obtained as described
earlier.22
molecular modeling studies (by d. chan). computational simulations were performed using the molecular dynamics package amber 743 implementing the all-atom nonpolarizable ff99 force field44 based on the force field of cornell
and co-workers.45 molecular mechanics parameters for 10 and
nadph were not present in the standard amber database
and thus were derived using antechamber.46 am1-bcc
partial charges were obtained from mopac.47 formal charges
of -1 and -4 were assigned to 10 and nadph, respectively.
starting coordinates for the simulations were furnished by
least-squares superimposition of the pteridine moiety of 10
onto inhibitors displayed in previously reported ternary complexes of pc dhfr (pdb code: 1klk)23 and human dhfr
(pdb code: 1ohj)48 using the molecular graphics package
sybyl 6.9.39 the carboxyalkoxy side chain of 10 was manually
rotated to minimize steric clashes with the enzyme. all
crystallographically determined h2o molecules were retained

except two, which were removed from the active site in order
to accommodate the dibenz[b,f]azepine moiety. the ternary
complexes were solvated in tip3 h2o by adding a 10 Ã¥ (pc
dhfr) or 9 Ã¥ (human dhfr) shell around the solute, raising
the total number of h2o molecules in the system to 7262 and
8106, respectively. all molecular dynamics simulations were
unrestrained and began with a 2000-step energy minimization
protocol consisting of cycles of steepest descent minimization,
followed by conjugate gradient minimization to remove unfavorable contacts between the enzyme, nadph, and 10.
periodic boundary conditions with a nonbonded cutoff of 10 Ã¥
were applied. dynamics runs were 0.5 ns in length and had a
time step of 2 fs. the pressure was regulated at 1 atm, and
the temperature was maintained at 298 k with the exception
of the final 20 ps, when the system was cooled to 1 k over a
period of 10 ps. the shake algorithm49 was applied to
constrain bonds involving hydrogen at their equilibrium
values. at the end, the complexes were subjected to a 2000step energy minimization procedure.

acknowledgment. this work was supported in part
by grant ro1-ai29904 (a.r.) from the national institute of allergy and infectious diseases. computer time
was generously provided by the research computing
core facility, dana-farber cancer institute.
references
(1) richman, d. d. hiv chemotherapy. nature 2001, 410, 9951001.
(2) meneÌndez-arias, l. targeting hiv: antiretroviral therapy and
development of drug resistance. trends pharmacol. sci. 2002,
23, 381-388.
(3) (a) moore, r. d. cost-effectiveness of combination hiv therapy;
3 years later. pharmacoeconomics 2000, 17, 325-330. (b) freedberg, k. a.; losina, e.; weinstein, m. c.; paltiel, a. d.; cohen,
c. j.; seage, g. r.; craven, d. e.; zhang, h.; kimmel, a. d.;
goldie, s. j. the cost-effectiveness of combination antiretroviral
therapy for hiv disease. n. engl. j. med. 2001, 344, 824-831.
(4) (a) kaplan, j. e.; hu, d. j.; holmes, k. k.; jaffe, h. w.; masur,
h.; de cock, k. m. preventing opportunistic infections in human
immunodeficiency virus-infected persons: implications for the
developing world. am. j. trop. med. hyg. 1996, 55, 1-11. (b)
moore, r. d.; chaisson, r. e. natural history of opportunistic
disease in an hiv-infected urban clinical cohort. ann. intern.
med. 1996, 124, 633-642.
(5) (a) piot, p. global aids epidemic: time to turn the tide. science
2000, 288, 2176-2178. (b) parker, r. the global hiv/aids
pandemic, structural inequalities, and the politics of international health. am. j. public health 2002, 92, 343-346.
(6) kovacs, j. a.; gill, v. j.; meshnick, s.; masur, h. new insights
into transmission, diagnosis, and drug treatment of pneumocystis carinii pneumonia. j. am. med. assoc. 2001, 286, 2450-2460.
(7) wong, s. y.; remington, j. s. biology of toxoplasma gondii.
aids 1993, 7, 299-316.
(8) (a) belanger, f.; derouin, f.; grangeot-keros, l.; meyer, l.
incidence and risk factors of toxoplasmosis in a cohort of human
immunodeficiency virus-infected patients: 1988-1995. hemoco and seroco study groups. clin. infect. dis. 1999, 28, 575581. (b) neuenburg, j. k.; brodt, h. r.; herndier, b. g.; bickel,
m.; bacchetti, p.; price, r. w.; grant, r. m.; schlote, w. hivrelated neuropathology, 1985 to 1999: rising prevalence of hiv
encephalopathy in the era of highly active antiretroviral therapy.
j. acquir. immune defic. syndr. 2002, 31, 171-177. (c) nath,
a.; sinai, a. p. cerebral toxoplasmosis. curr. treat. options
 xxxd122xxx . 2003, 5, 3-12.
(9) (a) horsburgh, c. r., jr.; gettings, j.; alexander, l. n.; lennox,
j. l. disseminated mycobacterium avium complex disease
among patients infected with human immunodeficiency virus.
clin. infect. dis. 2001, 33, 1938-1943. (b) pozniak, a. mycobacterial diseases and hiv. j. hiv ther. 2002, 7, 13-16. (b)
von reyn, c. f.; arbeit, r. d.; horsburgh, c. r.; ristola, m. a.;
waddell, r. d.; tvaroha, s. m.; samore, m.; hirschhorn, l. r.;
lumio, j.; lein, a. d.; grove, m. r.; tosteson, a. n. sources of
disseminated mycobacterium avium infection in aids. j. infect.
2002, 44, 166-170.
(10) guerrant, r. l. cryptosporidiosis: an emerging, highly infectious
threat. emerg infect dis. 1997, 3, 51-57. (b) clark d. p. new
insights into human cryptosporidiosis. clin microbiol. rev. 1999,
12, 554-563. (c) oldfield, e. c., iii. evaluation of chronic
diarrhea in patients with human immunodeficiency virus infection. rev. gastroenterol. disord. 2002, 2, 176-188.

2484

journal of medicinal chemistry, 2004, vol. 47, no. 10

rosowsky et al.

(11) (a) rosowsky, a.; forsch, r. a.; queener, s. f. inhibition of
pneumocystis carinii, toxoplasma gondii, and mycobacterium
avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement
in potency relative to trimethoprim and species selectivity
relative to  xxxd2968xxx . j. med. chem. 2002, 45, 233-242. (b)
rosowsky, a.; forsch, r. a.; queener, s. f. further studies on
2,4-diamino-5â€²-(2â€², 5â€²-disubstituted benzyl)pyrimidines as potent
and selective inhibitors of dihydrofolate reduces from three major
opportunistic pathogens of aids. j. med chem. 2003, 46, 17261736; see this paper for a list of papers from this laboratory from
1993 to 2002.
(12) (a) gangjee, a.; dubash, n. p.; queener, s. f. the synthesis of
new diaminofuro[2,3-d]pyrimidines with 5-biphenyl, phenoxyphenyl and tricyclic substitutions as  xxxg631xxx 
inhibitors. j. heterocycl. chem. 2000, 37, 935-942; see also
many other papers from this group prior to 2000. (b) gangjee,
a.; adair, o.; queener, s. f. synthesis of 2,4-diamino-6-(thioarylmethyl) xxxd3047xxx [2,3-d]pyrimidines as  xxxg631xxx 
inhibitors. bioorg. med. chem. 2001, 9, 2929-2935. (c) gangjee,
a.; zheng, y.; mcguire, j. j.; kisliuk, r. l. synthesis of classical
and nonclassical, partially restricted, linear, tricyclic 5-deazaantifolates. j. med. chem. 2002, 45, 5173-5181.
(13) (a) piper, j. r.; johnson, c. a.; krauth, c. a.; carter, r. l.;
hosmer, c. a.; queener, s. f.; borotz, s. e.; pfefferkorn, e. r.
lipophilic antifolates as agents against opportunistic infections.
1. agents superior to  xxxd3442xxx  and  xxxd2968xxx  against
toxoplasma gondii and pneumocystis carinii in in vitro evaluations. j. med. chem. 1996, 39, 1271-1280. (b) suling, w. j.;
seitz, l. e.; pathak, v.; westbrook, l.; barrow, e. w.; zywnovan ginkel, s.; reynolds, r. c.; piper, j. r.; barrow, w. r.
antimycobacterial activities of 2,4-diamino-5-deazapteridine
derivatives and effects on mycobacterial  xxxg631xxx .
antimicrob. agents chemother. 2000, 44, 2784-2793.
(14) (a) stevens, m. f. g.; phillip, k. s.; rathbone, d. l.; oâ€™shea, d.
m.; queener, s. f.; schwalbe, c. h.; lambert p. a. structural
studies on bioactive compounds. 28. selective activity of triazenyl-substituted pyrimethamine derivatives against pneumocystis carinii  xxxg631xxx . j. med. chem. 1997, 40,
1886-1893. (b) cody, v.; chan, d.; galitsky, n.; rak, d.; luft,
j. r.; pangborn, w.; queener, s. f.; laughton, c. a.; stevens,
m. f. g. structural studies on bioactive compounds. 30. crystal
structure and molecular studies on the pneumocystis carinii
 xxxg631xxx  cofactor complex with tab, a highly
selective antifolate. biochemistry 2000, 39, 3556-3564.
(15) robson, c.; meek, m. a.; grunwaldt, j.-d.; lambert, p. a.;
queener, s. f.; schmidt, d.; griffin, r. j. nonclassical 2-diamino-5-aryl-6- xxxd3051xxx  antifolates: activity as inhibitors of  xxxg631xxx  from pneumocystis carinii and
toxoplasma gondii and as antitumor agents. j. med. chem.
1997, 40, 3040-3048.
(16) for selected clinical examples, see: (a) fischl, m. a.; dickinson,
g. m.; la voie, l. safety and efficacy of sulfamethoxazole and
trimethoprim prophylaxis for pneumocystis carinii pneumonia
in aids. j. am. med. assoc. 1988, 259, 1185-1189. (b) medina,
i.; mills, h, leuong, g.; hopewell, p. c.; lee, b.; modin, g.;
benowitz, n.; wofsy, c. b. oral therapy for pneumocystis carinii
pneumonia in the acquired immunodeficiency syndrome. a
controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. n. engl. j. med. 1990, 323, 776-782. (c)
podzamczer, d.; salazar, a.; jimenez, j.; consiglio, e.; santin,
m.; casanova, a.; rufi, g.; gudiol, g. intermittent trimethoprimsulfamethoxazole compared with dapsone-pyrimethamine for the
simultaneous primary prophylaxis of pneumocystis pneumonia
and toxoplasmosis in patients infected with hiv. ann. intern.
med. 1995, 122, 755-761. (d) fraser, i.; macintosh, i.; wilkins,
e. g. prophylactic effect of  xxxd1734xxx  for mycobacterium
avium complex infection: a previously unreported benefit. clin.
infect. dis. 1994, 19, 211.
(17) roudier, c.; caumes, e.; rogeaux, o.; bricaire, f.; gentilini, m.
adverse cutaneous reactions to trimethoprim-sulfamethoxazole
in patients with the acquired immunodeficiency syndrome and
pneumocystis carinii pneumonia. arch. dermatol. 1994, 130,
1383-1386.
(18) ma, l.; borio, l.; masur, h.; kovacs, j. a. pneumocystis carinii
dihydropteroate synthase but not  xxxg631xxx  gene
mutations correlate with prior trimethoprim-sulfamethoxazole
or dapsone use. j. infect. dis. 1999, 180, 1969-1978.
(19) (a) sattler, f. r.; frame, p.; davis, r.; nichols, l.; shelton, b.;
akil, b.; baughman, r.; hughlett, c.; weiss, w.; boylen, c. t.;
van der horst, c.; black, j.; powderly, w.; steigbigel, r. t.;
leedom, j. m.; masur, h.; feinberg, j.; benoit, s.; eyster, e.;
gocke, d.; beck. k.; lederman, m.; phari, j.; reichman, r.;
sacks, h. s.; soiero, r..  xxxd3442xxx  with  xxxd2462xxx  versus
trimethoprim-sulfamethoxazole for moderate to severe episodes
of pneumocystis carinii pneumonia in patients with aids: a
prospective, controlled multicenter investigation of the aids
clinical trials group protocol 029/031. j infect. dis. 1994, 170,

165-172. (b) fulton, b.; wagstaff, a. j.; mctavish, d.  xxxd3442xxx . a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of
pneumocystis carinii pneumonia. drugs 1995 49, 563-576.
falloon, j.; allegra, c. j.; kovacs, j.; oâ€™neill, d.; ogata-arakaki,
d.; feuerstein, i.; polis, m.; davey, r.; lane, h. c.; lafon, s.;
rogers, m.; zunich, k.; turlo, j.; tuazon, c.; parenti, d.; simon,
g.; masur, h.  xxxd2968xxx  with  xxxd2462xxx  for the treatment of
pneumocystis pneumonia (pcp) in aids patients. clin. res.
1990, 38, 361a.
kovacs, j. a.; allegra, c. j.; beaver, j.; boarman, d.; lewis,
m.; parrillo, j. e.; chabner, b.; masur, h. characterization of
de novo folate synthesis in pneumocystis carinii and toxoplasma
gondii: potential for screening therapeutic agents. j. infect. dis.
1989, 160, 312-320.
rosowsky, a.; cody, v.; galitsky, n.; fu, h.; papoulis, a. t.;
queener, s. f. structure-based design of selective inhibitors of
 xxxg631xxx : synthesis and antiparasitic activity of
2,4-diaminopteridine analogues with a bridged diarylamine side
chain. j. med. chem. 1999, 42, 4853-4860.
cody, v.; galitsky, n.; luft, j. r.; pangborn, w.; rosowsky, a.;
queener, s. f. structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of pneumocystis carinii
 xxxg631xxx  ternary complex with pt653 and nadph. acta crystallogr. 2002,  xxxd58xxx , 946-954.
rosowsky, a.; fu, h.; queener, s. f. synthesis of new 2,4diaminopyrido[2,3-d]pyrimidines and 2,4-diaminoquinazolines
with bulky dibenz[b,f]azepine and dibenzo[a,d]cycloheptene substituents at the 6-positiion as inhibitors of dihydrofolate reductases from pneumocystis carinii, toxoplasma gondii, and mycobacterium avium. j. heterocycl chem. 2000, 37, 921-926.
haque, k. h.; hardie, k. m.; proctor, g. r. novel aromatic
systems. part ix. synthesis and substitutions of dibenzo[b,f]azepin-2-one. j. chem. soc., perkin trans. 1 1972, 539-542.
chang, v. h. t. synthesis of 2-hydrocycarbamazepine. a metabolite of carbam-azepine. j. heterocycl. chem. 1983, 20, 237238.
(a) stadler, p. a.; frey, a. j.; troxler, r.; hofmann, a. selective
reduction and oxidation reactions of lysergic acid derivates. helv.
chim. acta 1964, 47, 756-769. (b) saa, j. m.; capo, m.; marti,
c.; garcia-raso, a. oxidative degradation of 6-hydroxy-1,2,3,4tetrahydroisoquinolines and 7-hydroxy-2-benazepines. a novel
route to heterocyclic quinones. j. org. chem. 1990, 55, 288292. (c) islam, l.; skibo, e. b.; dorr, r. t.; alberts, d. s.
structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating dna cleaving
agents. j. med. chem. 1991, 34, 2954-2961. (d) giethlen, b.;
schaus, j. m. oxidation of indolines with fremyâ€™s salt: a
mechanistic proposal. tetrahedron lett. 1997, 38, 3483-3486.
(d) kraus, g. a.; selvakumar, n. a novel fremyâ€™s salt-mediated
oxidation and rearrangement of anilines into amino orthodiketones. applications to the synthesis of pyrrolobenzodiazepines. tetrahedron lett. 1999, 40, 2039-2040.
taylor, e. c.; portnoy, r. c.; hochstetler, d. c.; kobayashi, t.
pteridines. xxxviii. synthesis of some 2,4-diamino-6-substituted methylpteridines. a new route to pteroic acid. j. org.
chem. 1975, 40, 2347-2351.
rosowsky, a.; forsch, r. a.; queener, s. f.; bertino, j. r.
synthesis of 2,4-diaminopteridines with bulky lipophilic groups
at the 6-position as inhibitors of pneumocystis carinii, toxoplasma gondii, and mammalian  xxxg631xxx . pteridines 1997, 8, 173-187.
kuyper, l. f.; roth, b.; baccanari, d. p.; ferone, r.; beddell,
c. r.; champness, j. n.; stammers, d. k.; dann, j. g.;
norrington, f. e.; baker, d. j.; goodford. p. j. receptor-based
design of  xxxg631xxx  inhibitors: comparison of
crystallographically determined enzyme binding with enzyme
affinity in a series of carboxy-substituted trimethoprim analogues. j. med. chem. 1985, 28, 303-311.
broughton, m. c.; queener, s. f. pneumocystis carinii  xxxg631xxx  used to screen potential antipneumocystis drugs.
antimicrob. agents chemother. 1991, 35, 1348-1355.
chio, l.-c.; queener, s. f. identification of highly potent and
selective inhibitors of toxoplasma gondii  xxxg631xxx . antimicrob. agents chemother. 1993, 37, 1914-1923. note
that in our original paper in which the activity of 6 against t.
gondii tachyzoites was reported22 the reference cited for the [3h]uracil incorporation assay method should have been 16b instead
of 17c.
then, r. l.; hartman, p. g.; kompis, i.; stephan-guÌˆldner, m.;
stoÌˆckel, k. epiroprim. drugs future 1994, 19, 446-449.
gangjee, a.; vasudevan, a.; queener, s. f.; kisliuk, r. l. 2,4diamino-5-deaza-6-substituted  xxxd3047xxx [2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases. j. med. chem. 1996, 39, 1438-1446.
wang, y.; bruenn, j. a.; queener, s. f.; cody, v. isolation of
rat  xxxg631xxx  gene and characterization of recombinant enzyme. antimicrob. agents chemother. 2001 45, 2517-

(20)

(21)

(22)

(23)

(24)

(25)
(26)
(27)

(28)

(29)

(30)

(31)
(32)

(33)
(34)

(35)

 xxxg631xxx  inhibitors

(36)
(37)

(38)

(39)
(40)

(41)

2523. note that the si of compound 6, referred to as pt653 in
this paper, was inadvertently listed as 1.9, instead of 13.9 for
pc versus human dhfr. however, as evident from the ic50
values and the accompanying discussion, the potency and
selectivity of 6 for pc versus human and for pc versus rat dhfr
are very similar.
structural studies on rat dhfr by crystallography are in
progress in the laboratory of dr. vivian cody, hauptmanwoodward medical research institute, buffalo, ny.
for computational studies on the set of  xxxd3047xxx [2,3-d]pyrimidine
analogues synthesized by suling and co-workers,13b as well as
our lead compound 6, see: debnath, a. k. pharmacophore
mapping of a series of 2,4-diamino-5-deazapteridine inhibitors
of mycobacterium avium complex  xxxg631xxx , see
j. med. chem. 2002, 45, 41-53. for a more recent modeling
study in which several of these structures were docked into a
homology model of ma dhfr derived from a published 3d
structure for mycobacterium tuberculosis dhfr, see: kharkar,
p. s.; kulkarni, v. m. a proposed model of mycobacterium avium
complex  xxxg631xxx  and its utility for drug design.
org. biomol. chem. 2003, 1, 1315-1322.
(a) dhople, a. l. in vitro activity of epiroprim, a dihydrofolate
reductase inhibitor, singly and in combination with brodimoprim
and dapsone, against mycobacterium leprae. int. j. antimicrob.
agents 1999, 12, 319-323. (b) dhople, a. l. antimicrobial
activities of  xxxg631xxx  inhibitors, used singly or
in combination with dapsone, against mycobacterium ulcerans.
j. antimicrob. chemother. 2001, 47, 93-96.
tripos, inc., st. louis, mo.
in the discussion of the interactions of 10 with pc and human
dhfr, the ring to which the 2â€²-substituent is attached is called
the a-ring, the azepine ring is called the b-ring, and the third
ring in the tricyclic system is called the c-ring.
andrews, p.; dooley, m. role of molecular recognition in drug
design. in: textbook of drug design and discovery, 3rd ed.;
krogsgaard-larsen, p., liljefors, t., madsen, u., eds.; taylor
and francis publishers: london, uk, 2000; pp 35-53.

journal of medicinal chemistry, 2004, vol. 47, no. 10 2485
(42) (a) cody, v.; rosowsky, a. crystal structure determination of
human dhfr binary complexes with tmp and modeling studies
of tmp analogues. aacr proc. 2002, 43, 1021. (b) personal
communication from dr. vivian cody.
(43) case, d. a.; pearlman, d. a.; caldwell, j. w.; cheatham, t. e.,
iii; wang, j.; ross, w. s.; simmerling, c. l.; darden, t. a.; merz,
k. m.; stanton, r. v.; cheng, a. l.; vincent, j. j.; crowley, m.;
tsui, v.; gohlke, h.; radmer, r. j.; duan, y.; pitera, j.;
massova, l.; seibel, g. l.; singh, u. c.; weiner, p. k.; kollman,
p. a. amber 7; university of california, san francisco, 2002.
(44) wang, j.; cieplak, p.; kollman, p. a. how well does a restrained
electrostatic potential (resp) model perform in calculating
conformational energies of organic and biological molecules? j.
comput. chem. 2000, 21, 1049-1074.
(45) cornell, w.; cieplak, p.; bayly, c.; gould, i.; merz, k.; ferguson,
d.; spellmeyer, d.; fox, t.; caldwell, j.; kollman, p. a. a second
generation force field for the simulation of proteins, nucleic acids,
and organic molecules. j. am. chem. soc. 1995, 117, 5179-5197.
(46) jakalian, a.; bush, b. l.; jack, d. b.; bayly, c. i. fast, efficient
generation of high-quality atomic charges. am1-bcc model: i.
methodol. j. comput. chem. 2000, 21, 132-146.
(47) stewart, j. j. p. rossi, i.; hu, w. p.; lynch, g. c.; liu, y. p.;
chuang, y. y.; li, j.; cramer, c. j.; fast, p. l.; truhlar, d. g.
mopac version 5.09mn; university of minnesota, minneapolis,
1999.
(48) cody, v.; galitsky, n.; luft, j. r.; pangborn, w.; rosowsky, a.;
blakley, r. l. comparison of two independent crystal structures
of human  xxxg631xxx  ternary complexes with
 xxxd532xxx  phosphate and the
very tight-binding inhibitor pt523. biochemistry 1997, 36,
13897-13903.
(49) ryckaert, j.; ciccoti, g.; berendsen, h. numerical integration
of the cartesian equations of motion for a system of constraints.
j. comput. phys. 1977, 23, 327-341.

jm030599o

